November 14,2007

Baucus Comments On Avandia “Black Box” Warning From FDA

Finance leaders have been investigating FDA, drug company history on diabetes drug

Washington, DC –U.S. Senate Finance Committee Chairman Max Baucus (D-Mont.)
commented today on the FDA’s announcement that it will add additional “black box”
labeling to the diabetes drug Avandia. Chairman Baucus, along with Finance Ranking
member Chuck Grassley (R-Iowa), has been investigating safety issues surrounding the
drug. The Finance Committee has jurisdiction over Medicare and Medicaid, major
purchasers of medicines like Avandia.

“Concerns have been voiced for some time about Avandia’s possible role in heart
attacks in patients taking the drug, and it’s about time for a firm word from the
FDA about the potential risks,”
Baucus said. “I will continue to work with Senator
Grassley to find out more about the FDA’s and GlaxoSmithKline’s actions with
regard to Avandia, and will watch closely the FDA's comparison study of Avandia
and other drugs. Patients and the taxpayers purchasing this drug through Medicare and Medicaid have a right to a thorough inquiry.”

# # #